MedTrace Logo

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

NCT06993922 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-30

No results posted yet for this study

Summary

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

Conditions

  • Dexmedetomidine
  • Adjuvant
  • Bupivacaine
  • Scalp Block
  • Postoperative Pain
  • Craniotomy

Interventions

OTHER

Scalp block

Patients will receive a scalp block with bupivacaine alone.

OTHER

Scalp block + Dexmedetomidine

Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993922 on ClinicalTrials.gov